ArticleMedicine2026
Mortality involving non-rheumatic valvular heart disease and atrial fibrillation in the United States: Long-term trends and implications.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Rheumatic valvular heart disease (NRVHD) and atrial fibrillation (AF) are major contributors to cardiovascular mortality in the U.S. Their coexistence increases the risk of stroke, heart failure, and death.This study examines national trends in deaths involving both NRVHD and AF in the United States from 1999 to 2023. Centers for disease control and prevention - Wide-Ranging Online Data for Epidemiologic Research data (1999-2023) were analyzed for adults with AF (I48) and NRVHD (I34-I36) as contributing causes of death. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population. Joinpoint regression analysis was used to determine average and annual percent change (AAPC) and annual percent change. From 1999 to 2023, a total of 141,846 deaths in the U.S. involved both AF and NRVHD. The AAMR increased from 2.98 in 1999 to 7.30 in 2023 (AAPC: 4.17; P < .001). Males had higher overall AAMR (5.31) (AAPC: 4.73) than females (4.02) (AAPC: 3.58). Non-hispanic Whites had the highest overall AAMR (5.17) while Hispanics had an AAMR of (1.88). Regionally, West had the highest overall AAMR (5.73), followed by the Northeast (4.81), the Midwest (4.79), and then the South (3.48). Majority of the deaths occurred in inpatient medical facilities (49,170 deaths, 35.0%). The age group 65 + showed the highest mortality (crude mortality rate: 11.93). Rural areas had higher overall AAMR (4.36) compared to urban areas (4.10). Deaths involving both AF and NRVHD increased from 1999 to 2023, with greater burden among older adults, males, rural areas, the West region, and non-Hispanic White population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.